Biogas yields and composition from oil-extracted halophilic algae residues in conventional biogas plants operated at high salinities.

CO2-induced climate change drives the development of renewable processes for industrial products. Algae processes can actively fix and convert CO2 into value adding products, such as oils. Algae lipids hence counteract climate change and provide access to renewable commodities. In this context, valorization of algal residues remaining after oil extraction is a challenge for the emerging cyclic bioeconomy. This study focuses on the valorization of oil-extracted algae residues derived from the halophilic strain Scenedesmus obliquus via anaerobic digestion. We examined the effect of prior oil extraction on microbial digestibility and increasing salt content in the substrate with regard to biogas yield and composition. Our cumulative data demonstrate that the supercritical CO2 oil extraction acts as a physical pretreatment that facilitates enhanced hydrolysis of both polymeric call wall carbohydrates and cellular proteins, providing methane yields of 213.2 LN kg-1 VS day-1. Methane yields were 20% higher than literature values obtained with the same algae strain in the absence of prior oil extraction. We obtained these superior results albeit all lipids and nonpolar proteins had been extracted from the biogas substrate. Our data indicate that continuous anaerobic digestion without loss of fermentation efficiency is feasible up to a salt concentration of 2% w/v, if conventional, agricultural biogas plants are gradually adapted to the salt content of the substrate. Monofermentation of the investigated oil-extracted algae residue is technically feasible at loading rates of 1.5 kg VS m-3 day-1, but a supplementation with carbohydrate rich biomass would prove beneficial to alleviate ammonia inhibition.

GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence.

We report that GTP cyclohydrolase (GCH1), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, is a key modulator of peripheral neuropathic and inflammatory pain. BH4 is an essential cofactor for catecholamine, serotonin and nitric oxide production. After axonal injury, concentrations of BH4 rose in primary sensory neurons, owing to upregulation of GCH1. After peripheral inflammation, BH4 also increased in dorsal root ganglia (DRGs), owing to enhanced GCH1 enzyme activity. Inhibiting this de novo BH4 synthesis in rats attenuated neuropathic and inflammatory pain and prevented nerve injury-evoked excess nitric oxide production in the DRG, whereas administering BH4 intrathecally exacerbated pain. In humans, a haplotype of the GCH1 gene (population frequency 15.4%) was significantly associated with less pain following diskectomy for persistent radicular low back pain. Healthy individuals homozygous for this haplotype exhibited reduced experimental pain sensitivity, and forskolin-stimulated immortalized leukocytes from haplotype carriers upregulated GCH1 less than did controls. BH4 is therefore an intrinsic regulator of pain sensitivity and chronicity, and the GTP cyclohydrolase haplotype is a marker for these traits.

Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype.

BACKGROUND: Carriers of a particular haplotype of the GTP cyclohydrolase gene (GCH1) had less pain after surgery for chronic lumbar radiculopathy and a decreased sensitivity to some experimental mechanical pain stimuli. Ex-vivo, GCH1 upregulation and BH4 production after forskolin stimulation were reduced, while baseline BH4 concentrations were not affected. This suggested that the haplotype may mainly exert its modulating function when the GCH1 system is provoked. The present study aimed at (i) testing this hypothesis and (ii) independently reproducing the pain-decreasing effects of a particular GCH1 haplotype having been previously associated with pain protection. METHODS: Experimental pain models with sensitization (local skin inflammation, dermal capsaicin application) and without sensitization (punctate pressure, blunt pressure, thermal and electrical pain) were assessed in 10 homozygous and 22 non-carriers of the particular GCH1 haplotype reportedly associated with pain protection. GCH1, iNOS upregulation and BH4 production were assessed ex-vivo in white blood cells after lipopolysaccharide stimulation for 24 h. RESULTS: Carriers of the particular GCH1 haplotype addressed in this study had higher thresholds to punctate mechanical pain (von Frey hairs) following local skin inflammation (18.1+/-11.3 vs. 9+/-2.8 g; p=0.005) and, to a lesser degree, to heat pain following capsaicin sensitization (35.2+/-0.9 vs. 36.6+/-2.4 degrees C; p=0.026). In contrast, heat and pressure thresholds and tolerance to electrical stimulation in pain models without sensitization did not differ among the genotypes. GCH1, BH4 and iNOS upregulation in white blood cells after lipopolysaccharide stimulation were decreased in carriers of the GCH1 haplotype, which verified that the genotype groups differed with respect to regulation of the biopterin pathway. CONCLUSIONS: This study verifies previous results that decreased GCH1 function or inducibility as a result of genetic polymorphisms protects against pain. This study extents previous results by showing that this pain protection is mainly conferred under conditions of hyperalgesia resulting from sensitization, supporting specific functions of BH4 in relation to particular aspects of pain.